Steven Cohen’s Abeona Therapeutics ABEO Stock Holding History

Steven Cohen’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-760,870	Closed	-$3.81M	–	2115
2023 Q4	$3.81M	Sell	760,870 -420,200	-36%	-$1.85M	0.01%	1012
2023 Q3	$4.97M	Buy	1,181,070 +49,647	+4%	+$188K	0.01%	882
2023 Q2	$4.56M	Sell	1,131,423 -19,225	-2%	-$67.2K	0.01%	846
2023 Q1	$3.24M	Hold	1,150,648	–	–	0.01%	896
2022 Q4	$3.54M	Buy	+1,150,648	New	+$4.3M	0.01%	828
2022 Q2	–	Sell	-128,000	Closed	-$1.01M	–	1379
2022 Q1	$1.01M	Hold	128,000	–	–	﹤0.01%	954
2021 Q4	$1.08M	Buy	+128,000	New	+$2.35M	﹤0.01%	901
2020 Q3	–	Sell	-44,000	Closed	-$3.21M	–	899
2020 Q2	$3.21M	Sell	44,000 -23,000	-34%	-$1.59M	0.02%	542
2020 Q1	$3.52M	Sell	67,000 -1,000	-1%	-$66.8K	0.03%	430
2019 Q4	$5.56M	Buy	+68,000	New	+$4.8M	0.03%	485
2018 Q1	–	Sell	-6,312	Closed	-$2.5M	–	908
2017 Q4	$2.5M	Sell	6,312 -1,962	-24%	-$811K	0.01%	703
2017 Q3	$3.53M	Buy	+8,274	New	+$2.22M	0.02%	598

Other funds holding ABEO

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

WSL

Western Standard LLC Los Angeles, California $295M AUM 40.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Steven Cohen's ABEO Position: Q1 2024 in Review

Steven Cohen sold out of Abeona Therapeutics (ABEO) in Q1 2024, closing a stake of 760,870 shares — an estimated $3.81M sold.

Steven Cohen first reported a position in ABEO in Q3 2017 and held it in 12 quarters. The position peaked at $5.56M in Q4 2019. 56 funds tracked by Wall St. Rank hold ABEO as of Q1 2024.

Steven Cohen reported no remaining Abeona Therapeutics position as of Q1 2024 after selling out during the quarter.
Steven Cohen sold 760,870 Abeona Therapeutics shares in Q1 2024, an estimated $3.81M.
Steven Cohen first reported a position in Abeona Therapeutics in Q3 2017 and held it in 12 quarters.
Steven Cohen's Abeona Therapeutics position peaked at $5.56M in Q4 2019.
56 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2024.

Based on Point72 Asset Management's 13F filing for Q1 2024, filed 15 May 2024.